G protein‐coupled receptor‐mediated autophagy in health and disease
British Journal of Pharmacology, EarlyView.G protein‐coupled receptors (GPCRs) constitute the largest and most diverse superfamily of mammalian transmembrane proteins. These receptors are involved in a wide range of physiological functions and are targets for more than a third of available drugs in the market. Autophagy is a cellular process involved in degrading damaged proteins and organelles
Devrim Öz‐Arslan +2 more
wiley +1 more source
Depletion of nuclear cytoophidia in Alzheimer's disease. [PDF]
Free NeuropatholIvanova A, Munoz DG, Woulfe J.
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
British Journal of Pharmacology, EarlyView.Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source
Metabolic mutations reduce antibiotic susceptibility of E. coli by pathway-specific bottlenecks. [PDF]
Mol Syst BiolLubrano P +14 more
europepmc +1 more source
Progress on the development of Class A GPCR‐biased ligands
British Journal of Pharmacology, EarlyView.Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales +20 more
wiley +1 more source
Relaxation Optimized Heteronuclear Experiments for Extending the Size Limit of RNA Nuclear Magnetic Resonance. [PDF]
J Am Chem SocShah A +4 more
europepmc +1 more source
Cancer Science, EarlyView.Our study found that epigenetic changes, particularly histone modifications regulating FGF1, contribute to osimertinib resistance. Targeting these modifications with BET inhibitors may offer new therapeutic strategies. ABSTRACT Osimertinib, a third‐generation EGFR‐tyrosine kinase inhibitor, is the first‐line therapy for lung cancer harboring EGFR ...
Yosuke Miyashita +20 more
wiley +1 more source
GART promotes the proliferation and migration of human non-small cell lung cancer cell lines A549 and H1299 by targeting PAICS-Akt-β-catenin pathway. [PDF]
Front OncolChen Z +7 more
europepmc +1 more source
Lnc‐TPT1‐AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression
Cancer Science, EarlyView.Overexpression of TPT1‐AS1 could suppress the malignant phenotype and purine synthesis activation of breast cancer through competitive interaction with CBP, subsequently reducing the promoter H3K27ac signal and transcription of ATIC. Therefore, targeting the TPT1‐AS1/CBP/ATIC axis may provide a useful strategy for the treatment of patients with breast ...
Yiyun Zhang +10 more
wiley +1 more source